Antonio Fernandez-Nebro
Antonio Fernandez-Nebro
Professor of Rheumatology
Dirección de correo verificada de uma.es - Página principal
TítuloCitado porAño
Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients
R Cervera, JC Piette, J Font, MA Khamashta, Y Shoenfeld, MT Camps, ...
Arthritis & Rheumatism: Official Journal of the American College of …, 2002
17152002
Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients
R Cervera, MA Khamashta, J Font, GD Sebastiani, A Gil, P Lavilla, ...
Medicine 82 (5), 299-308, 2003
12412003
Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients
R Cervera, R Serrano, GJ Pons-Estel, L Ceberio-Hualde, Y Shoenfeld, ...
Annals of the rheumatic diseases 74 (6), 1011-1018, 2015
573*2015
Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1,000 patients. European Working Party on Systemic Lupus …
R Cervera, MA Khamashta, J Font, GD Sebastiani, A Gil, P Lavilla, ...
Medicine 78 (3), 167-175, 1999
5041999
Antiphospholipid syndrome
R Cervera
Thrombosis research 151, S43-S47, 2017
320*2017
Euro-Phospholipid Project Group. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients
R Cervera, JC Piette, J Font, MA Khamashta, Y Shoenfeld, MT Camps, ...
Arthritis Rheum 46 (4), 1019-1027, 2002
2632002
Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised …
PJ Mease, D van der Heijde, CT Ritchlin, M Okada, RS Cuchacovich, ...
Annals of the rheumatic diseases 76 (1), 79-87, 2017
2022017
Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial)
D Isenberg, C Gordon, D Licu, S Copt, CP Rossi, D Wofsy
Annals of the rheumatic diseases 74 (11), 2006-2015, 2015
1732015
Osteoarticular complications of brucellosis.
JD Colmenero, JM Reguera, A Fernandez-Nebro, F Cabrera-Franquelo
Annals of the rheumatic diseases 50 (1), 23-26, 1991
1671991
Immunochip analysis identifies multiple susceptibility loci for systemic sclerosis
MD Mayes, L Bossini-Castillo, O Gorlova, JE Martin, X Zhou, WV Chen, ...
The American Journal of Human Genetics 94 (1), 47-61, 2014
1412014
Systemic lupus erythematosus in Europe at the change of the millennium: lessons from the “Euro-Lupus Project”
R Cervera
Autoimmunity reviews 5 (3), 180-186, 2006
1412006
Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised …
P Nash, B Kirkham, M Okada, P Rahman, B Combe, GR Burmester, ...
The Lancet 389 (10086), 2317-2327, 2017
1242017
Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists
A Fernández-Nebro, E Tomero, V Ortiz-Santamaría, MC Castro, A Olivé, ...
The American journal of medicine 118 (5), 552-556, 2005
1102005
Anti-neutrophil cytoplasmic antibodies in 566 European patients with systemic lupus erythematosus: prevalence, clinical associations and correlation with other autoantibodies …
M Galeazzi, G Morozzi, GD Sebastiani, F Bellisai, R Marcolongo, ...
Clinical and experimental rheumatology 16 (5), 541-546, 1998
1021998
Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase …
R Fleischmann, E Mysler, S Hall, AJ Kivitz, RJ Moots, Z Luo, R DeMasi, ...
The Lancet 390 (10093), 457-468, 2017
942017
BANK1 functional variants are associated with susceptibility to diffuse systemic sclerosis in Caucasians
B Rueda, P Gourh, J Broen, SK Agarwal, C Simeon, N Ortego-Centeno, ...
Annals of the rheumatic diseases 69 (4), 700-705, 2010
922010
Anticardiolipin and anti-β2GPI antibodies in a large series of European patients with systemic lupus erythematosus
GD Sebastiani, M Galeazzi, A Tincani, JC Piette, J Font, F Allegri, ...
Scandinavian journal of rheumatology 28 (6), 344-351, 1999
921999
A large-scale genetic analysis reveals a strong contribution of the HLA class II region to giant cell arteritis susceptibility
FD Carmona, SL Mackie, JE Martín, JC Taylor, A Vaglio, S Eyre, ...
The American Journal of Human Genetics 96 (4), 565-580, 2015
902015
Multicenter longitudinal study of B-lymphocyte depletion in refractory systemic lupus erythematosus: the LESIMAB study
A Fernández-Nebro, JLM de la Fuente, L Carreno, MG Izquierdo, ...
Lupus 21 (10), 1063-1076, 2012
852012
Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematosus: a systematic review
T Cobo-Ibáñez, E Loza-Santamaría, JM Pego-Reigosa, AO Marqués, ...
Seminars in arthritis and rheumatism 44 (2), 175-185, 2014
822014
El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.
Artículos 1–20